Progression-free survival was significantly longer in the pazopanib plus paclitaxel group than in the paclitaxel only group ( median 635 months [ 95 % CI 536-1102 ] vs 349 months [ 201-566 ] ; hazard ratio 042 [ 95 % CI 025-069 ] ; p = 00002 ) .